31 results about "Serological assay" patented technology

The invention discloses a neutralizing swine monoclonal antibody pO18-40 and a neutralizing swine monoclonal antibody pO18-43 for foot and mouth disease virus type O. The amino acid sequences of a heavy chain variable region (VH) and a light chain variable region (VL) of the antibody pO18-40 are respectively as shown in SEQ ID No. 1 and SEQ ID No. 2; the amino acid sequences of VH and VL of the antibody pO18-43 are respectively as shown in SEQ ID No. 3 and SEQ ID No. 4. The antibody obtained by the invention is a full-swine-source antibody, can specifically neutralize the classical strain of the O-type foot-and-mouth disease virus, and can clearly distinguish the classical strain of the O / Cathay topological type from the variant strain of the O / Cathay topological type. A key antigen epitope recognized by the antibody is located at the 149th amino acid of a VP1 protein G-H ring, and the site is a key site of O / Cathay strain antigen variation and vaccine immune protection. The antibody provided by the invention provides an important tool and theoretical basis for serological detection of O-type FMDV, vaccine immune effect evaluation and optimal design of broad-spectrum vaccines.

The utility model provides a kind of adjustable spectrum shaking table belongs to medical diagnosis and detection technical field, the device includes tray, disposable test piece one, disposable test piece two, drive base and homogenizing plate, installation groove is opened in tray, several LED lamp beads are evenly distributed in installation groove, and clamping strip is symmetrically arranged and fixedly connected at installation groove slot mouth edge, drive base is set in tray lower end, and homogenizing plate is clamped on clamping strip, the device is according to the deficiency of existing disposable test piece, by setting LED lamp bead, homogenizing plate cooperate drive base, it can guarantee that the style of different viscosity has very good shaking effect, eliminate the intensity, angle difference of artificial shaking, improve result consistency, the device can be operated without professional training, can directly use marketable disposable test piece, support a variety of serological detection, equipment operation is simple, overall cost is lower, it is favorable to market promotion, with good market prospect before sale.

This invention proposes a random forest-based diagnostic method for Pneumocystis jirovecii pneumonia (PCP), comprising the following steps: collecting case data to form a raw dataset; cleaning and normalizing the feature encoding of the raw dataset; calculating the importance score of each feature based on three indices: permutation importance, Gini importance, and mutual information, converting it into a feature sampling probability distribution, and selecting features with sampling probabilities higher than a preset threshold; constructing a random forest model and training and optimizing it; validating the model performance using a test set and outputting the trained PCP diagnostic model; inputting standardized test samples into the diagnostic model and outputting diagnostic results. This invention solves the industry problems of intolerance to traditional invasive diagnoses, high false positive / false negative rates in routine serological tests, and insufficient generalization ability of existing machine learning models, providing non-invasive, efficient, and universal technical support for early PCP diagnosis, and is suitable for clinical application in medical institutions at all levels.

The invention relates to the technical field of biological detection, in particular to a saliva RF-IgM rapid detection kit and application thereof, and the saliva RF-IgM rapid detection kit comprises a saliva pretreatment module, a signal amplification module and a result interpretation module. The invention provides an RF-IgM rapid detection method based on a saliva sample and application thereof, and solves the problems of invasiveness and time consumption of traditional serological detection. Technical difficulties in saliva detection, including the problems of insufficient sensitivity and high false negative rate caused by large IgM molecular weight and saliva mucoprotein interference, are solved. Non-invasive, rapid and convenient detection of rheumatoid factors is achieved, patient compliance is improved, and the kit is suitable for outpatient real-time detection (POCT), primary medical treatment and large-scale population early screening.

The invention discloses an F1 monoclonal antibody and application thereof, the F1 monoclonal antibody is used for specifically binding a 6HB structural domain in a spike protein S2 subunit of SARS-CoV-2, the F1 monoclonal antibody comprises VHCDR1-3 of a heavy chain variable region and VLCDR1-3 of a light chain variable region, the amino acid sequences of the VHCDR1, the VHCDR2 and the VHCDR3 are respectively shown as SEQ ID NO.1, SEQ ID NO.3 and SEQ ID NO.5, and the amino acid sequences of the VLCDR1, the VLCDR2 and the VLCDR3 are respectively shown as SEQ ID NO.2, SEQ ID NO.4 and SEQ ID NO.6. The invention further discloses an application of the F1 monoclonal antibody. The F1 monoclonal antibody can neutralize SARS-CoV-2 virus infection, and has important application value in serological detection of new coronavirus, preparation of a reagent for new coronavirus infection detection and a reagent for new coronavirus antigen or antibody detection.

This disclosure provides a novel serological method for detecting zoonotic viral infections, such as porcine cytomegalovirus (PCMV) infection or porcine lymphotropic herpesvirus (PLHV) infection, in subjects at any stage of disease development. More specifically, this disclosure provides an automated multiplexed immunoassay for the rapid and simultaneous detection of one or more anti-PCMV antibodies or anti-PLHV antibodies in the biological fluid of subjects suspected of being infected with PCMV or PLHV.

This disclosure relates to coronavirus assays, diagnostic methods, treatment methods, and compositions related thereto. In certain embodiments, this disclosure relates to ACE2 receptor binding domain peptides and uses in serological assays and vaccination methods.

The invention provides application of a biomarker in serum detected by a Raman spectrum in preparation of a product for predicting or detecting non-Hodgkin lymphoma, and belongs to the technical field of medical diagnosis. A spectroscopy basis is provided for mass serological detection data of a patient and early identification of the lymphoplasmal cell lymphoma and the diffuse large B-cell lymphoma, and important information is provided for rapid early identification of the lymphoplasmal cell lymphoma and the diffuse large B-cell lymphoma.

A polynucleotide, a kit, an isothermal detection method and a method for predicting premature birth, the method for predicting premature birth comprising: analyzing the expression profile of any one or at least two gene sets in a maternal sample, and predicting whether the subject will have premature birth according to the expression profile. The present application detects the expression amount of the marker gene in the serum of pregnant women for the first time, which is used for the prediction of premature birth risk of pregnant women without clinical symptoms. The main advantage is serological detection, no need to make an appointment in advance like ultrasound, non-invasive detection, no need for vaginal or cervical sampling, and good detection process experience.

This disclosure relates to coronavirus assays, diagnostic methods, treatment methods, and compositions related thereto. In certain embodiments, this disclosure relates to ACE2 receptor binding domain peptides and uses in serological assays and vaccination methods.

The application relates to the technical field of markers, in particular to application of biomarkers for identifying acute and chronic stages of brucellosis. A series of biomarkers related to acute and chronic stages of brucellosis are screened and found, and the biomarkers are significantly different between patients with acute and chronic brucellosis. The biomarkers can be used to realize acute and chronic staging of brucellosis, and have high sensitivity and specificity and good diagnostic efficiency. The application provides a new molecular diagnostic tool for acute and chronic staging of brucellosis, solves the problems of low specificity of existing serological detection and incapability of accurately judging clinical stages, and has a wide application prospect.

The invention discloses a novel anti-echinococcus monoclonal antibody, a hybridoma cell strain and application of the novel anti-echinococcus monoclonal antibody, and belongs to the technical field of biomedicine and immunology. The preservation number of the hybridoma cell strain Anti-Em-11 disclosed by the invention is CGMCC (China General Microbiological Culture Collection Center) No. 46598. According to the present invention, the specific monoclonal antibody is successfully prepared and identified, and Western blot and indirect immunofluorescence experiments prove that the obtained monoclonal antibody has high specificity on the recombinant protein. The invention lays a solid foundation for serological diagnosis of the echinococcosis and remarkably enriches the existing serological detection technical system.

The invention discloses an HBV infected mouse model and a construction method and application thereof, and the construction method comprises the following steps: step 1, taking a healthy female HBV-Tg mouse with a positive HBV marker as a liver donor, taking out the liver through an operation, and cutting the liver into small blocks; step 2, taking a healthy female NPG mouse with severe combined immunodeficiency as a receptor animal, pulling the maximum leaf of the liver to the outside of the abdominal cavity through an operation, placing a liver tissue block of the HBV-Tg mouse on the exposed liver parenchyma surface of the NPG mouse, performing auxiliary fixation, then returning the liver back to the abdominal cavity, and then suturing; 3, the copy number of HBV DNA in NPG mouse serum is measured, and if the two continuous detection values are remarkably higher than the background value and the index can be continuously maintained at a certain level in the subsequent observation period, the HBV infected mouse model is successfully constructed. According to the invention, the process from donor sampling to receptor transplantation can be completed within several hours, and the model can be verified through serological detection 1-2 weeks after operation, so that the modeling period is greatly shortened.

The present disclosure provides a novel serological method for detecting viremia or a latent human-livestock co-occurrence virus infection (e.g., porcine cytomegalovirus (PCMV) or porcine lymphotropic herpesvirus (PLHV) infection) in a subject at any stage of development. More specifically, the present disclosure provides automated multiplex immunoassays for the rapid and simultaneous detection of one or more anti-PCMV or anti-PLHV antibodies in a biological fluid of a subject suspected of being infected with PCMV or PLHV.

The invention discloses a method and system for correcting two-dimensional ultrasonic image video data of autoimmune hepatitis cirrhosis, and relates to the technical field of data processing, and the method comprises the following steps: obtaining two-dimensional ultrasonic image video original data and corresponding clinical diagnosis data of a patient with autoimmune hepatitis cirrhosis; performing classification extraction on the original data and the clinical diagnosis data to obtain dynamic image sequence data, ultrasonic characteristic parameter data, hepatic fibrosis grading data and serological detection data; based on the dynamic image sequence data, judging texture consistency, contour integrity and motion artifact interference degree of images at different time nodes to determine a quality evaluation result of the image sequence; based on the ultrasonic characteristic parameter data, multiple groups of parameter measurement results of the same detection part are compared, so that the typical ultrasonic characteristics of different lesion stages are effectively presented, the early cirrhosis identification accuracy and the curative effect monitoring precision are greatly improved, and the missed diagnosis and misdiagnosis risks are reduced.

The invention provides a prevention and control method for cynomolgus monkeys based on SRV virus detection, and belongs to the technical field of cynomolgus monkey SRV virus detection, the cynomolgus monkeys after birth are subjected to intensive SRV antigen PCR and SRV antibody ELISA detection and are fed and managed in groups, negative animals after 9 months are subjected to annual quarantine, positive animals stop quarantine and are subjected to positive management by default, and the cynomolgus monkeys after birth are subjected to SRV antigen PCR detection and SRV antibody ELISA detection by default. The antibody positive and / or antigen positive belongs to the positive category. According to the method, SRV antigen PCR and SRV antibody ELISA detection are densely carried out on the cynomolgus monkeys after birth, grouping feeding management is carried out, early prevention and control can cut off a transmission chain, recessive infection can be effectively recognized, partially-infected monkeys are low in antibody reaction and even cannot be detected, but long-term detoxification can be achieved, recessive infection sources can be accurately removed by combining PCR and serological detection in the baby monkey period, and the method has the advantages of high specificity, high sensitivity, high sensitivity and the like. Although the detection cost is invested in the early stage, huge losses such as treatment, animal elimination and experiment repetition caused by disease outbreak in the future can be avoided.

The invention provides ECM1 as a marker for serological detection of liver injury and application of the ECM1. Specifically, the invention provides liver injury evaluation equipment which comprises an input module, a processing module and an output module. According to the liver injury assessment equipment, various liver injury risks can be accurately judged according to the concentration of the input liver injury biomarker ECM1.

The invention relates to the technical field of biological medicines, and discloses an ELISA kit and application thereof in early screening of heart diseases. The ELISA kit based on the competition method is obtained by constructing and screening a specific VHH antibody through a library and coating the specific VHH antibody in a pore plate as a coating antibody to obtain a pre-coated plate. The ELISA kit is convenient to operate and good in inter-batch stability, is a non-invasive serological detection method, and can be used for effective auxiliary screening of fetal congenital heart disease risks in early pregnancy.

This disclosure provides for method for the diagnosis, prognosis and treatment of inflammatory bowel disease (IBD) and clinical subtypes of IBD in a subject by detecting the presence or level of one or more immune responses to self and microbial antigens in a sample from a subject.

An immunoassay is described that enables a precise evaluation of immune responses in individuals exposed to Mpox or vaccinated with MVA, with high sensitivity and specificity. The serological assay targets three Orthopoxvirus antigens, MPXV-B6R, MPXV-A27L, and VACV-B5R, which are sufficient to quantify antibody responses to both MVA-vaccination (VACV-B5R) and, separately, infection (MPXV-B6R). The three antigen titres can be combined in a simple function [sum of ((MPXV-B6R) / VACV-B5R) and (MPXV-A27L)] to provide a numerical test score that can be compared with a reference (threshold) value to differentiate between post infection and post vaccination immune responses.

The invention relates to the technical field of serological detection and evaluation, and particularly discloses an application of a group of cfDNA sequences as talaromyces marneffei infection risk evaluation markers, a serological detection method has the advantages of high sensitivity, high specificity, non-invasiveness and short time consumption, a detection result can be used as intermediate data, and the method is suitable for clinical application. The method is suitable for evaluation reference of invasive pulmonary aspergillosis. The marker has the advantages of short sequence (100-200bp), high abundance, high conservative property and low fungal homology, is widely used in blood circulation, and is non-invasive in sampling. According to the present invention, the qPCR is combined with the specific primer probe (SEQ ID NO.4-12, and the probe contains the fluorescence report / quenching group) to detect, the efficiency verification results show that the sensitivity is high, the specificity and the AUC value are superior to the traditional ELISA method, the mcfDNA detection in the blood can be achieved, and the risk assessment in the whole infection process is supported;

The invention discloses a monoclonal antibody, a hybridoma cell strain, a detection kit, a detection method and application, and relates to the technical field of animal epidemic disease prevention and control. According to the invention, a monoclonal antibody is obtained and is obtained by secreting a hybridoma cell strain DRV-4G3 with the preservation number of CGMCC (China General Microbiological Culture Collection Center) No.46567. The specific monoclonal antibody aiming at the duck reovirus muNS protein is prepared and obtained through an immune mouse and splenocyte fusion technology, the monoclonal antibody can recognize the muscovy duck reovirus and the novel reovirus at the same time, and the method for detecting the duck reovirus is established on the basis of the monoclonal antibody and can be used for large-scale serological detection. And reovirus vaccine immune antibody dynamic monitoring is achieved, and good development and practical application values are achieved.

This invention provides the application of serine palmitoyltransferase small subunit A (SPTSSA) as a biomarker in the preparation of kits for early diagnosis and / or prognostic prediction of breast cancer, belonging to the field of biomedical technology. Through bioinformatics analysis, histological verification, and serological detection, this invention systematically explores the expression characteristics of SPTSSA in breast cancer and its relationship with the tumor microenvironment, and evaluates its potential application value as a prognostic biomarker for breast cancer, hoping to provide potential targets for personalized treatment of breast cancer. Furthermore, this invention confirms SPTSSA as a novel breast cancer biomarker, which is of great significance for the diagnosis, prognosis, and treatment of breast cancer, providing a theoretical basis for SPTSSA-targeted therapeutic strategies.

The application discloses an ABO genotyping composition and kit based on a multiple asymmetric PCR probe melting curve and application. The application can realize accurate ABO genotyping in one batch of PCR reactions, and the whole detection process is simple, rapid, accurate and efficient, and has high practical value. The application makes up for the shortcomings of the existing serological detection method, has the advantages of standardization, low cost and low technical barrier for clinical popularization, and has a wide application prospect in ABO genotyping for Chinese population.

The application belongs to the technical field of biology and relates to a broad-spectrum monoclonal antibody for recognizing a linear antigen epitope at the C-terminal of foot-and-mouth disease virus VP2 protein and application thereof. The monoclonal antibody pOTB-1 is successfully constructed, the amino acid sequence of the heavy chain variable region is as shown in SEQ ID No. 6, and the amino acid sequence of the light chain variable region is as shown in SEQ ID No. 7. The biological activity of the antibody is verified by indirect immunofluorescence test, enzyme-linked immunosorbent assay and Western-blot. The antibody exhibits broad-spectrum reactivity to O type and A type FMDV and has strong binding affinity. The antibody recognizes a continuous linear B cell epitope at the C-terminal of the structural protein VP2. The epitope sequence is highly conserved among FMDV O type, A type and Asia1 type, which indicates that there is an inter-type common antigen site in the capsid protein VP2. A competitive ELISA detection method is established based on biotinylated pOTB-1, which provides a tool for the prevention and control of FMDV and serological detection, and lays a foundation for the design of FMDV marker vaccine and the evaluation of immunization effect.

OF THE INVENTION SEROLOGICAL MARKER FOR THE LATENT FORM OF TOXOPLASMOSIS In the present invention, inventors screened the bradyzoite proteome for immunogenic protein candidates in an unbiased manner and identified the Bradyzoite Serological Marker (BSM) as a second serological biomarker for Toxoplasma chronicity in mice. BSM serology correctly distinguishes cyst-bearing mice with a sensitivity and specificity of 97.96% (IC95: 89.31 - 99.90) and 100.0% (IC95: 86.20 - 100.0) respectively. In humans, both bradyzoite markers BCLA and BSM are in moderate agreement (kappa=0.308) and BSM serology is unexpectedly positive in 30% of patients with past immunity, raising many questions. Nevertheless, bradyzoite serology could provide new reference standards for studying the pathophysiology of chronic toxoplasmosis in humans, especially cyst carriage, which has been poorly described. Thus the invention relates to a new Toxoplasma gondii protein, hereafter referred as BSM, a new serological marker whose expression is restricted to the latent form of Toxoplasmosis (bradyzoite / cyst).

The invention discloses an F11 monoclonal antibody and application thereof, the F11 monoclonal antibody is used for specifically binding a 6HB structural domain in a spike protein S2 subunit of SARS-CoV-2, the F11 monoclonal antibody comprises VHCDR1-3 of a heavy chain variable region and VLCDR1-3 of a light chain variable region, amino acid sequences of the VHCDR1, the VHCDR2 and the VHCDR3 are respectively shown as SEQ ID NO.1, SEQ ID NO.3 and SEQ ID NO.5, and amino acid sequences of the VLCDR1, the VLCDR2 and the VLCDR3 are respectively shown as SEQ ID NO.2, SEQ ID NO.4 and SEQ ID NO.6. The invention further discloses a preparation method of the F11 monoclonal antibody. The F11 monoclonal antibody can neutralize virus infection of SARS-CoV-2, and has important application value in serological detection of new coronavirus, preparation of a reagent for detecting new coronavirus infection and a reagent for detecting new coronavirus antigen or antibody.

The application discloses a kind of recombinant proteins, the amino acid sequence of the described recombinant protein is as shown in SEQ ID NO:2;The recombinant protein is pigeon circovirus jone spread antigen.And the preparation method of the pigeon circovirus jone spread antigen and the application of the pigeon circovirus jone spread antigen are disclosed.The application deletes the basic amino acid sequence of pigeon circovirus Cap protein N end 2~44 by the 2~44, and inserts the truncated Cap protein sequence into pET-32a expression vector, successfully overcome the problem that pigeon circovirus Cap protein cannot be expressed or the expression amount is extremely low in escherichia coli, and the expressed protein includes soluble protein, with good immunogenicity, can be applied to genetic engineering vaccine and serological detection method etc. research.

The invention discloses a 6G3 monoclonal antibody and application thereof, the 6G3 monoclonal antibody is used for specifically binding a 6HB structural domain in a spike protein S2 subunit of SARS-CoV-2, the 6G3 monoclonal antibody comprises VHCDR1-3 of a heavy chain variable region and VLCDR1-3 of a light chain variable region, the amino acid sequences of VHCDR1, VHCDR2 and VHCDR3 are respectively shown as SEQ ID NO.1, SEQ ID NO.3 and SEQ ID NO.5, and the amino acid sequences of VLCDR1, VLCDR2 and VLCDR3 are respectively shown as SEQ ID NO.2, SEQ ID NO.4 and SEQ ID NO.6. The invention further discloses a preparation method of the 6G3 monoclonal antibody. The 6G3 monoclonal antibody can neutralize SARS-CoV-2 infection, and has important application value in serological detection of new coronavirus, preparation of a reagent for new coronavirus infection detection and a reagent for new coronavirus antigen or antibody detection.

The invention relates to the technical field of antibodies, and particularly provides a truncated fragment of African swine fever virus C129R protein, an antibody or an antigen binding fragment of the antibody and application of the truncated fragment and the antibody. The amino acid sequence of the truncated fragment C129R delta C is coded by SEQ ID NO: 1, and the truncated fragment C129R delta C has improved immunogenicity. The antibody specifically bound with the C129R protein or the antigen binding fragment of the antibody comprises a heavy chain variable region as shown in SEQ ID NO: 2 and a light chain variable region as shown in SEQ ID NO: 4; the blocking rate of the monoclonal antibody 3C10 is higher than 90%. On the basis of the core material, a kit for detecting the indirect ELISA antibody and the blocking ELISA antibody is constructed. The two kits both show high sensitivity, high specificity and good repeatability, and an efficient and reliable tool is provided for serological detection of African swine fever.